Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-86974680 in advanced non-small cell lung cancer
NCT06116786Phase 1Active, not recruiting
- Sponsor
- Johnson & Johnson
- Start
- Nov 2023
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of jnj-86974680 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Johnson & Johnson. Primary endpoints: Number of Participants with Adverse Events by Severity and Number of Participants with Dose Limiting Toxicities. Started Nov 2023; status: active, not recruiting.
02
Drugs
jnj-86974680
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06116786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06116786.